Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Fiche publication
Date publication
juin 2017
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
Tous les auteurs :
Andersson M, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Perez EA
Lien Pubmed
Résumé
VELVET Cohort 1 demonstrated the applicability of pertuzumab, trastuzumab, and vinorelbine as an alternative first-line treatment regimen for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who cannot receive docetaxel. Co-infusion of pertuzumab and trastuzumab may reduce clinic time and medical resource utilization. We report results from Cohort 2, in which pertuzumab and trastuzumab were co-infused, followed by vinorelbine.
Mots clés
HER2-positive, Metastatic breast cancer, Pertuzumab, Trastuzumab, Vinorelbine
Référence
Oncologist. 2017 Jun;: